The epidemiology, diagnosis and treatment of COVID-19

Abstract In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. This paper reviews the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, are discussed in this article. In addition, registered trials investigating treatment options for COVID-19 infection are listed.

[1]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[2]  Andrew D. Ellington,et al.  Real-Time Sequence-Validated Loop-Mediated Isothermal Amplification Assays for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) , 2015, PloS one.

[3]  E. De Clercq,et al.  Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. , 2006, Journal of medicinal chemistry.

[4]  Kwok-Hung Chan,et al.  Consistent Detection of 2019 Novel Coronavirus in Saliva , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Heshui Shi,et al.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.

[6]  C. Zheng,et al.  Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19) , 2020 .

[7]  Rui Liu,et al.  Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020 , 2020, Clinica Chimica Acta.

[8]  K. To,et al.  Development and Evaluation of Novel Real-Time Reverse Transcription-PCR Assays with Locked Nucleic Acid Probes Targeting Leader Sequences of Human-Pathogenic Coronaviruses , 2015, Journal of Clinical Microbiology.

[9]  Z. Fayad,et al.  CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) , 2020, Radiology.

[10]  Philippe Colson,et al.  Chloroquine for the 2019 novel coronavirus SARS-CoV-2 , 2020, International Journal of Antimicrobial Agents.

[11]  J. Sung,et al.  Factors Associated with Psychosis among Patients with Severe Acute Respiratory Syndrome: A Case-Control Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Shibo Jiang,et al.  Recent advances in the detection of respiratory virus infection in humans , 2020, Journal of medical virology.

[13]  A. Heim,et al.  Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion , 2020, Journal of Clinical Virology.

[14]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[15]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.

[16]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[17]  Malik Peiris,et al.  Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.

[18]  X. Mariette,et al.  Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus , 2015, Arthritis & rheumatology.

[19]  Bernhard Liebl,et al.  Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  L. Katz,et al.  The cobas® 6800/8800 System: a new era of automation in molecular diagnostics , 2017, Expert review of molecular diagnostics.

[21]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[22]  C. Zheng,et al.  Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia , 2020, Radiology.

[23]  Q. Tao,et al.  Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases , 2020, Radiology.

[24]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[25]  Susanne Pfefferle,et al.  Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[26]  M. Martínez.  Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.

[27]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Edward Y Lee,et al.  Acute Middle East Respiratory Syndrome Coronavirus: Temporal Lung Changes Observed on the Chest Radiographs of 55 Patients. , 2015, AJR. American journal of roentgenology.

[29]  P. Horby,et al.  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. , 2016, The New England journal of medicine.

[30]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[31]  L. Shen,et al.  Clinical trial analysis of 2019‐nCoV therapy registered in China , 2020, Journal of medical virology.

[32]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[33]  L. Yang,et al.  Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak , 2020, International Journal of Infectious Diseases.

[34]  D. Raoult,et al.  Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century , 2007, International Journal of Antimicrobial Agents.

[35]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[36]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[37]  Wei Zhang,et al.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes , 2020, Emerging microbes & infections.

[38]  G. Panayiotakopoulos,et al.  Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event , 2020, bioRxiv.

[39]  Kwok-Hung Chan,et al.  Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens , 2020, Journal of Clinical Microbiology.

[40]  Don Klinkenberg,et al.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[41]  T. Dörner,et al.  Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.

[42]  S. Haeghebaert,et al.  BULLETIN EUROPÉEN SUR LES MALADIES TRANSMISSIBLES / EUROPEAN COMMUNICABLE DISEASE BULLETIN , 2003 .

[43]  A. Wilder-Smith,et al.  Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak , 2020, Journal of travel medicine.

[44]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[45]  David A. Schwartz,et al.  Potential Maternal and Infant Outcomes from Coronavirus 2019-nCoV (SARS-CoV-2) Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections , 2020, Viruses.

[46]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[47]  Rajaa Al-Raddadi,et al.  Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome , 2017, American journal of respiratory and critical care medicine.

[48]  Roberto Cauda,et al.  New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.

[49]  G. Spier,et al.  Clinical evaluation of multiplex RT-PCR assays for the detection of influenza A/B and respiratory syncytial virus using a high throughput system. , 2019, Journal of virological methods.

[50]  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, Emerging microbes & infections.

[51]  Z. Tong,et al.  Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak , 2020, Journal of medical virology.

[52]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[53]  Yicheng Fang,et al.  Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR , 2020, Radiology.

[54]  Philippe Brouqui,et al.  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 , 2020, International Journal of Antimicrobial Agents.

[55]  Gilbert Greub,et al.  Ten years of R&D and full automation in molecular diagnosis. , 2016, Future microbiology.

[56]  Chengyu Jiang,et al.  Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.

[57]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[58]  Y. Choi,et al.  One-Pot Reverse Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) for Detecting MERS-CoV , 2017, Front. Microbiol..

[59]  X. de Lamballerie,et al.  Of chloroquine and COVID-19 , 2020, Antiviral Research.

[60]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[61]  Chengcheng Yu,et al.  Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[62]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[63]  gui-qiang Wang,et al.  A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option , 2020, Journal of medical virology.

[64]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[65]  L. Chen,et al.  [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[66]  Joy Y. Feng,et al.  The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus , 2020, The Journal of Biological Chemistry.

[67]  Shou-Jiang Gao,et al.  HIV-1 did not contribute to the 2019-nCoV genome , 2020, Emerging microbes & infections.

[68]  Joy Y. Feng,et al.  Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir , 2019, Viruses.

[69]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[70]  E. Marlowe,et al.  High-Throughput Testing of Urogenital and Extragenital Specimens for Detection of Chlamydia Trachomatis and Neisseria Gonorrhoeae with Cobas® CT/NG , 2017, European journal of microbiology & immunology.

[71]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[72]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[73]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[74]  J. Mackenzie,et al.  Reservoirs and vectors of emerging viruses , 2013, Current Opinion in Virology.

[75]  Jianhong Wu,et al.  Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions , 2020, Journal of clinical medicine.

[76]  G. Zeng,et al.  Pandemic planning in China: Applying lessons from severe acute respiratory syndrome , 2008, Respirology.

[77]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[78]  Jun Liu,et al.  Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing , 2020, Radiology.

[79]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[80]  S. Rayner,et al.  Does SARS‐CoV‐2 has a longer incubation period than SARS and MERS? , 2020, Journal of medical virology.

[81]  A. Elfiky,et al.  Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 , 2020, Life Sciences.

[82]  Peikai Huang,et al.  Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion , 2020, Radiology.

[83]  Vineet D. Menachery,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[84]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[85]  G. Kampf,et al.  Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents , 2020, Journal of Hospital Infection.

[86]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[87]  Science multicenter collaboration group of Department of,et al.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[88]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[89]  Michael Proschan,et al.  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.

[90]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[91]  S. Mulangu.  843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics , 2019, Open Forum Infectious Diseases.

[92]  V. Wong,et al.  Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.

[93]  A. Cassone,et al.  Effects of chloroquine on viral infections: an old drug against today's diseases , 2003, The Lancet Infectious Diseases.

[94]  Jie Hao,et al.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection , 2020, Frontiers of Medicine.

[95]  Wei Zhang,et al.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. , 2020, Bioscience trends.

[96]  Jincun Zhao,et al.  A Rapid and Specific Assay for the Detection of MERS-CoV , 2018, Front. Microbiol..